I did not want to reply to your same old sh%t that Cordis says about Taxus until after today, so spin this data my friend.
"The TAXUS II two-year follow-up included the largest prospective angiographic and IVUS two-year sub-study population (210 patients) in interventional cardiology. Angiographic data demonstrated stable late loss out to two years with sustained statistical benefit over the control group. The benefit in percent net volume obstruction as the primary endpoint at six months was also maintained out to two years, as demonstrated by the IVUS sub- study data."
The LARGEST EVER f/u in cardiology with both angio and IVUS!!
From Columbo on Taxus II:
"This data indicates that TAXUS stents may prevent -- rather than merely delay -- in-stent restenosis. The large patient cohorts and long-term angiographic and IVUS data provide an especially rich source of information on the excellent performance of the TAXUS system."
On Taxus IV:
"The results support safety and efficacy, as demonstrated by low rates of target lesion revascularization (retreatment rate, or TLR) that were maintained at two years. The TAXUS group reported a 5.6 percent (36/645) TLR rate compared with 17.5 percent (112/640) in the control group. The follow-up rate at two years was outstanding with 97 percent of patients returning. The rate of patients living free of TLR events was 94.4 percent at two years for the TAXUS group, as compared to 82.6 percent for the control group."
How about that % f/u!!!!
More on Taxus IV:
"The TAXUS IV results at two years are exceptional and support the long- lasting safety and efficacy of paclitaxel-eluting stent technology," said Gregg W. Stone, M.D., the study's Principal Investigator and Professor of Medicine, Columbia University Medical Center in New York. "These outcomes establish the durability of the TAXUS stent in a broad range of complex patients and blockages, representing a true medical advance. At two-year follow-up, the incremental benefits of having received the TAXUS stent system rather than a bare-metal stent continue to increase with no evidence of late catch-up apparent."
Thsi destroys all arguments that JNJ tried to spin on the Taxus IV data a year ago!
It is safe, it is effective, and their sales force is kicking JNJ's ass!
Three letter acronyms have always left me cold. in a proper message the 3 letter acronym is defined once so that the reader has some idea of the meaning. I believe it is a negative from the context but it is not clear.
One thing that seems to be lost is that the DES stents were accepted on the grounds that they were an improvement on bare metal stents. It is likely that BSX bare metal stent is superior to the bare metal JNJ stent and that is one of the reasons for the difference in performance.
Right -- BSX no good FUD FUD blah blah blah
Taxus doesn't work FUD FUD blah blah blah
BSX headed for bankruptcy FUD FUD blah blah blah
Bunch of cheating liars FUD FUD blah blah blah
The market, users, and all the analysts, just can't see the truth FUD FUD blah blah blah
Soooo, who you gonna believe, powerplay, or your lying eyes....